Introduction and Objective: There is a gap in understanding diabetes technology use among older people with type 1 and type 2 diabetes (pwt1d, pwt2d). A survey in Germany, Austria and Switzerland investigated the association between age and diabetes technology use.Methods: Between 2023/11 and 2024/01, pwd and parents of children with diabetes reported their use of CGM and AID systems. Logistic regression identified the impact of age in use of CGM and AID systems.Results: A total of 2292 responses from pwt1d and 613 from pwt2d were analyzed. In pwt1d, CGM use approached 100% with no significant decline with age (OR 0.99, CI 0.98 -1.01, p>0.05); in pwt2d, CGM use increased with age (OR 1.02, CI 1.01 -1.04, p<0.05). AID use in pwt1d was significantly higher in younger age groups OR 0.99, CI 0.98 -0.99, p<0.05), but remained stable up to 80 years in pwt1d older than 30 years, with 31% of those older than 80 years still using AIDs.Conclusion: CGM use is approaching 100% in pwt1d, while it increases with age in pwt2d, possibly due to treatment intensification or safety concerns. AID systems show substantial uptake up to 80 years. Despite potential selection bias, these findings highlight the widespread adoption of diabetes technologies among older PWD and underscore the importance of tailoring technologies to support independent living in older age.
N. Hermanns: Advisory Panel; Dexcom, Inc., Abbott Diagnostics. Speaker’s Bureau; Abbott Diagnostics. Advisory Panel; Roche Diabetes Care. D. Ehrmann: Advisory Panel; Dexcom, Inc. Speaker’s Bureau; Dexcom, Inc. Consultant; Roche Diabetes Care. Speaker’s Bureau; Roche Diabetes Care, Sanofi, Eli Lilly and Company, Boehringer-Ingelheim. T. Roos: None. L. Heinemann: Consultant; Dexcom, Inc., Roche Diabetes Care. Board Member; Lifecare. Stock/Shareholder; Science Consulting in Diabetes GmbH, Profil Institut für Stoffwechselforschung GmbH, diateam GmbH. Consultant; Indigo. J.K. Mader: Advisory Panel; Abbott. Speaker’s Bureau; Abbott. Advisory Panel; Eli Lilly and Company. Speaker’s Bureau; Eli Lilly and Company. Stock/Shareholder; elyte Diagnostics. Advisory Panel; embecta. Speaker’s Bureau; embecta, Menarini. Advisory Panel; Medtronic. Speaker’s Bureau; Dexcom, Inc. Advisory Panel; Dexcom, Inc., Novo Nordisk A/S. Speaker’s Bureau; Novo Nordisk A/S. Advisory Panel; Roche Diabetes Care. Speaker’s Bureau; Roche Diabetes Care. Advisory Panel; Sanofi. Speaker’s Bureau; Sanofi. Advisory Panel; Biomea Fusion, PharmaSens, Tingo Medical. Stock/Shareholder; decide Clinical Software. P. Diem: Board Member; PharmaSens. Advisory Panel; Abbott Diagnostics. M. Resl: Research Support; Dexcom, Inc. Advisory Panel; Abbott. D. Brandt: None. B. Kulzer: Advisory Panel; Abbott, Dexcom, Inc. Consultant; Becton, Dickinson and Company. Other Relationship; Insulet Corporation, AstraZeneca. Board Member; Sanofi-Aventis Deutschland GmbH. Advisory Panel; Roche Diabetes Care, Novo Nordisk.
Abbott Diabetes Care, Ascensia, Germany, Dexcom, Germany, Diabetes Center Berne, Roche, Ypsomed
Source link
Leave a Reply